Central Venous Catheter Infection, Intensive Care Unit, Lock Solution, Prevention, Taurolidine
Conditions
Brief summary
This study aimed to assess effectiveness of a taurolidine based lock solution in preventing the infections of central venous catheter (CVC) in intensive care unit (ICU) cases.
Detailed description
The central venous catheter (CVC) is highly frequent in the intensive care unit (ICU), with an average use rate between 32% and 80% among adult ICU patients. The utilization of CVC in ICUs has escalated over the past decade, accompanied by a corresponding increase in problems related to their usage. Taurolidine is a nontoxic substance having antibacterial impacts counter to mutually gram-positive and -negative bacteria, additionally to fungus. It decreases biofilm development and doesn't develop resistance to antibiotics, since it serves as an antiseptic rather than an antibiotic Consequently, it may function as a locking mechanism.
Interventions
DRUGSaline
Central venous catheters (CVCs) were locked with 2ml saline as a control group.
DRUGTigecycline and heparin
Central venous catheters (CVCs) were locked with 2ml of a solution comprising tigecycline 5mg/ml and heparin 500 IU/ml.
DRUGTaurolidine-citrate-heparin
Central venous catheters (CVCs) were locked with 2ml of a solution containing taurolidine-citrate-heparin (1.35% taurolidine, 4% citrate, and 500 IU/ml heparin).
Sponsors
Tanta University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 21 years. * Both genders. * Patients admitted to the intensive care unit (ICU) requiring central venous catheter insertion.
Exclusion criteria
* Cases with active infections, hemorrhage or bleeding disorders, infections within insertion place. * History of allergy to taurolidine, tigecycline, heparin, and citrate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Positive bacterial growth | 30 days after the procedure | Positive bacterial growth of a swab was recorded. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of catheter-related bloodstream infection | 30 days after the procedure | Assessment of catheter-related bloodstream infection was recorded. |
| Assessment of central venous catheter infection | 30 days after the procedure | Assessment of central venous catheter (CVC) infection was recorded. |
| Lenght of intensive care unit stay | 30 days after the procedure | Lenght of intensive care unit (ICU) stay was recorded. |
| Incidence of mortality | 30 days after the procedure | Incidence of mortality was recorded. |
Countries
Egypt
Outcome results
None listed